Seeking Alpha

Argus lines up United Therapeutics (UTHR -1.4%) as an undervalued name in the healthcare sector,...

Argus lines up United Therapeutics (UTHR -1.4%) as an undervalued name in the healthcare sector, as it maintains a Buy rating on the biotech concern. Analysts with the firm expect Argus to hit its 2012 sales target, as they raise their price target on shares by $8 to $60.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector